The non-binding insider buying indications are a modest positive signal of management alignment, but lack of commitment and share amounts limits conviction. Monitor for actual insider purchases via Form 4 filings to gauge conviction. The ATM remains available for company affiliate use, which could create modest dilution over time.
Price Chart
Executive Summary
Summit Therapeutics disclosed that its Audit Committee and independent directors approved company affiliates to purchase shares under the existing ATM facility with JP Morgan. Separately, CEO Robert Duggan, Co-CEO Mahkam Zanganeh, and COO/CFO Manmeet Soni indicated they are likely to purchase shares in the near term, but no binding commitments or share amounts were provided.
Key Facts
- Audit Committee and independent directors approved company affiliates to purchase shares under the ATM with JP Morgan.
- CEO Robert Duggan, Co-CEO Mahkam Zanganeh, and COO/CFO Manmeet Soni indicated they are likely to purchase shares under the ATM in the near term.
- No number of shares or binding commitments were disclosed for insider purchases.
- Any insider purchases would be at prevailing market bid price or better.
- The ATM was previously disclosed; this filing provides an update on potential insider participation.
Financial Impact
No dollar amounts or share counts disclosed; potential insider buying at market prices could signal alignment but is non-binding.
Risk Factors
- Insider purchase indications are non-binding and may not materialize.
- ATM share sales by company affiliates could dilute existing shareholders.
- No financial data or guidance provided to assess fundamental outlook.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001599298-26-000049 |
| Document: 0001599298-26-000049-index-headers.html | 0001599298-26-000049 |
| Document: 0001599298-26-000049-index.html | 0001599298-26-000049 |
| Document: 0001599298-26-000049.txt | 0001599298-26-000049 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $17.40 $17.85 | ▲ +2.59% | ▲ +1.77% | $16.75 (−3.71%) |
Sep 14, 2026 18d ago | 8-K | $18.42 $16.90 | ▼ −8.25% | ▼ −8.36% | $16.75 (−9.04%) |
Sep 3, 2026 29d ago | 8-K | $17.13 $17.55 | ▲ +2.45% | ▲ +3.60% | $16.75 (−2.19%) |
Aug 26, 2026 5w ago | 8-K | $14.23 $14.60 | ▲ +2.60% | ▲ +2.72% | $16.75 (+17.74%) |
Aug 5, 2026 8w ago | 8-K | $13.53 $15.10 | ▲ +11.60% | ▲ +11.25% | $16.75 (+23.84%) |
Jul 22, 2026 10w ago | 8-K | $14.74 $12.80 | ▼ −13.16% | ▼ −10.76% | $16.75 (+13.67%) |
Jun 12, 2026 16w ago | Insider Cluster | $14.01 $13.75 | ▼ −1.86% | ▼ −2.53% | $16.75 (+19.59%) |
Jun 12, 2026 16w ago | Institutional Cluster | $14.01 $13.75 | ▼ −1.86% | ▼ −2.53% | $16.75 (+19.59%) |
Jun 11, 2026 16w ago | Institutional Cluster | $13.08 $14.07 | ▲ +7.57% | ▲ +7.14% | $16.75 (+28.10%) |
Jun 9, 2026 16w ago | S-3ASR | $13.05 $13.88 | ▼ −6.36% | ▼ −2.93% | $16.75 (−28.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access